| Today’s Big NewsMar 11, 2024 |
| By Eric Sagonowsky,Fraiser Kansteiner,Zoey Becker,Angus Liu,Kevin Dunleavy The unrelenting churning of time means many things to many people. For pharma executives, it’s a constant reminder of the need for new launches to supplant old meds. |
|
|
|
By Annalee Armstrong Eli Lilly’s eczema medicine lebrikizumab cleared skin and provided itch relief in a study that was specifically designed for people with skin of color. |
By Conor Hale The KnowU device is designed to one day be fitted onto the skin as an adhesive patch or simply worn on the wrist, with sensors that use radio waves to gauge the body’s glucose levels. |
By Angus Liu J&J and Legend have submitted two more overall survival updates for Caryvkti since the original data release last year, Legend's CEO said on an analyst call. The FDA is expected to release more data on the CAR-T therapy later this week, ahead of an advisory committee meeting set for Friday. |
|
Wednesday, March 27, 2024 | 10am ET / 7am PTThere can be numerous challenges encountered during biopharmaceutical process development. Join usfor an important look at formulation development specifically. Featuring real-world examples, this insightful discussion will explore key challenges, as well as the latest techniques and solutions for effectively overcoming current obstacles. Register now. 
|
|
By Annalee Armstrong Novartis’ BTK inhibitor remibrutinib reduced disease activity in patients with the skin disease hidradenitis suppurativa, potentially setting up another indication for the pharma to tackle with the BTK inhibitor. |
By Conor Hale According to the FDA, a potential leak could lead to a dangerous loss of cerebrospinal fluid as well as introduce infections into the nervous system. |
By Zoey Becker The company presented positive data from a phase 2 study in mild-to-moderate hidradenitis suppurativa at the American Academy of Dermatology's annual meeting on Sunday. The disease setting currently has no approved treatment options. |
By Max Bayer Acelyrin is looking to right the ship after a topsy-turvy 2023 and is equipped with new psoriatic arthritis data to do just that. The company reported a statistically significant improvement in the number of patients reporting a 50% improvement in symptoms compared to placebo. |
By Nick Paul Taylor Eli Lilly is biting the hands that fed the weight-loss hype machine, calling out people who use the jabs to fit in a smaller dress or tuxedo in one ad and emphasizing that “obesity is a matter of health” in a second TV spot. |
By Nick Paul Taylor Incyte has laid down a marker in its pursuit of Regeneron and Sanofi’s Dupixent in prurigo nodularis, linking its oral challenger to significant improvements in itch and disease severity in a phase 2 study. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," join Conor Hale, Senior Editor of Fierce Medtech, and Andrea Park, Deputy Editor of Fierce Life Sciences, as they share the highlights of this year's Fierce Medtech Fierce 15. |
|
|---|
|
|
|
Monday, April 22, 2024 | 10am ET / 7am PTExplore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
Whitepaper Explore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
